Chinese Medical Journal最新文献

{"title":"A deep learning model using endoscopic images for differential diagnosis of intestinal lymphoma.","authors":"Lingying Zhao, Zixuan He, Weifeng Huang, Shoubin Ning, Bairong Li, Wen Tang, Jing Hu, Pengpeng Xu, Hongmei Yi, Chunhua Zhou, Chunhui Ouyang, Yongjun Wang, Taojing Ran, Duowu Zou, Yubei Gu","doi":"10.1097/CM9.0000000000003723","DOIUrl":"10.1097/CM9.0000000000003723","url":null,"abstract":"","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":" ","pages":"2824-2826"},"PeriodicalIF":9.1,"publicationDate":"2026-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13593088/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144689051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of machine learning-based predictive models for evaluating risk in the contralateral ear among patients with unilateral sudden sensorineural hearing loss.","authors":"Xiaohui Zhao, Yun Gao, Chunyan Liu, Dayong Wang, Qiuju Wang","doi":"10.1097/CM9.0000000000004230","DOIUrl":"10.1097/CM9.0000000000004230","url":null,"abstract":"<p><strong>Background: </strong>Sequential bilateral sudden sensorineural hearing loss (Se-BSSHL) may occur after an initial unilateral episode, but the risk factors for contralateral ear involvement remain unclear. This research aims to identify risk factors associated with the occurrence of contralateral ear in patients suffering from sudden sensorineural hearing loss (SSHL). By leveraging machine learning algorithms, the study uses patients' demographic and clinical data to develop a predictive model.</p><p><strong>Methods: </strong>We conducted an analysis on clinical data from 939 patients admitted to the Ear Department of the Chinese PLA General Hospital from 2008 to 2022, categorizing them into unilateral sudden sensorineural hearing loss (USSHL) and sequential bilateral sudden sensorineural hearing loss (Se-BSSHL) groups. Stratified sampling was executed to maintain a proportional representation of unilateral versus bilateral cases, leading to the creation of seven internal and three external datasets. Variable selection was performed using a decision tree-based recursive feature elimination method. We applied five-fold cross-validation on the internal datasets and conducted model testing on the external datasets. Four machine learning algorithms-random forest, extreme gradient boosting, logistic regression, and support vector machine-were used to build the predictive model and conduct external validation. Model efficacy was primarily appraised using the area under the receiver operating characteristic curve (AUC-ROC), calibration curves, decision curve analysis (DCA), and additional performance metrics including accuracy, precision, recall, and F1-score on the test set. The influence of the variables was illustrated through Shapley value plots. Statistical methods such as the t -test, analysis of variance, and chi-squared test were used.</p><p><strong>Results: </strong>We observed a 12.57% (118/939) incidence rate of contralateral ear complications in USSHL patients with otherwise normal hearing. The predictive model incorporated 19 variables, among them, age, hearing loss degree, and sex are the three most significant features influencing the occurrence in the healthy ear of the USSHL group. An increase in age and a more severe degree of hearing loss are risk factors for the occurrence of the disease, and females have a higher risk of disease occurrence. Other high-risk test indicators for disease occurrence can be summarized and categorized into two types of risk factors: lipoprotein dysfunction (total cholesterol, high-density lipoprotein cholesterol, apolipoprotein A1) and inflammation (eosinophils, lymphocyte count, neutrophil count). The AUC of the model on the external test reached 0.77, with an accuracy of 88%, a precision of 84%, a recall of 88%, and an F1 value of 0.85 using the default classification threshold of 0.5, demonstrating robust predictive capabilities.</p><p><strong>Conclusion: </strong>This investigation elucidates","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":" ","pages":"2760-2769"},"PeriodicalIF":9.1,"publicationDate":"2026-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13593222/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148788767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perioperative dexmedetomidine reduces the risk of postoperative complications in high-risk patients undergoing non-cardiac surgery: A randomized controlled trial.","authors":"Zhaoting Meng, Ting Ding, Wei Zhao, Lina Guo, Meilin Li, Zhaolong Zhao, Yang Zhang, Chunjing Li, Dongliang Mu, Dongxin Wang","doi":"10.1097/CM9.0000000000003648","DOIUrl":"10.1097/CM9.0000000000003648","url":null,"abstract":"<p><strong>Background: </strong>Dexmedetomidine may suppress the surgery-induced inflammatory response, which is considered the underlying mechanism of postoperative complications. This study was designed to investigate whether perioperative dexmedetomidine could decrease the risk of postoperative complications among high-risk patients.</p><p><strong>Methods: </strong>This multicenter randomized controlled trial is a superiority trial. Central randomization was used. Elderly patients (age ≥60 years) with revised cardiac risk index (RCRI) ≥3 and scheduled for major non-cardiac surgery were enrolled. Patients in dexmedetomidine group received intraoperative dexmedetomidine (a loading dose of 0.5 μg/kg followed by 0.3 μg·kg -1 ·h -1 ) as adjuvant to general anesthesia and postoperative dexmedetomidine (2 μg/h for 72 h) as supplementation to patient-controlled analgesia with sufentanil. Patients in the control group received an equivalent dose of normal saline as placebo during anesthesia and sufentanil only for postoperative analgesia. The primary outcome was the incidence of major postoperative complications including neurologic, cardiovascular, renal, pulmonary coagulation, infectious, and gastrointestinal systems within postoperative 30 days. Secondary outcomes included pain intensity, sleep quality, postoperative length of in-hospital stay, and medical expenses during hospitalization. Neutrophil-to-lymphocyte ratio (NLR) was used to monitor inflammatory response.</p><p><strong>Results: </strong>This study included 272 patients, with similar median age (70 years vs . 69 years) and median RCRI (both 3) between dexmedetomidine and control groups. The incidence of major postoperative complications in the dexmedetomidine group was significantly lower than that in the control group (38.2% [52/136] vs . 52.9% [72/136], relative risk [RR] = 0.722, 95% confidence interval (CI) 0.554-0.942, P = 0.015). Postoperative in-hospital stay was shorter in the dexmedetomidine group than that in the control group (mean difference [MD] = -1 day, 95% CI: -2 to 0 days, P = 0.013). Other secondary outcomes were comparable between the two groups. The highest NLR within postoperative first 3 days in the dexmedetomidine group was lower than that in the control group (MD = -2.1, 95% CI: -4.1 to -0.3, P = 0.037). The proportion of all drug-related adverse events were comparable between the two groups.</p><p><strong>Conclusion: </strong>Dexmedetomidine, infused from the beginning of anesthesia to postoperative 72 h, decreased the risk of postoperative complications in high-risk elderly patients undergoing non-cardiac surgery.</p><p><strong>Trial registration: </strong>No. ChiCTR2000030566 at www.chictr.org.cn.</p>","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":" ","pages":"2770-2779"},"PeriodicalIF":9.1,"publicationDate":"2026-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13593056/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144607588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erianin induces GSDMD-dependent pyroptosis and synergistically enhances doxorubicin efficacy via the PI3K/AKT signaling pathway in diffuse large B-cell lymphoma.","authors":"Hanwei Mei, Minghan Qiu, Ruxue Liu, Teng Song, Zhanhua Gao, Qiaonan Zhang, Yayun Wang, Jie Hao, Ming Gao, Zhen Yang, Huaqing Wang","doi":"10.1097/CM9.0000000000003634","DOIUrl":"10.1097/CM9.0000000000003634","url":null,"abstract":"<p><strong>Background: </strong>Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma and is characterized by high aggressiveness and rapid growth. Erianin, a natural compound derived from the Chinese herb Dendrobium , has been shown to exhibit anticancer effects in certain types of cancer; however, its role and mechanism of action in DLBCL have not yet been reported. Therefore, this study aimed to investigate the potential of erianin as a therapeutic drug for DLBCL.</p><p><strong>Methods: </strong>The cell counting kit-8 assay, lactate dehydrogenase release assay, flow cytometry, and 5-ethynyl-2'-deoxyuridine (EdU) assay were used to assess the inhibitory effect of erianin on DLBCL cells. RNA sequencing, western blotting, immunofluorescence, and flow cytometry were used to investigate the molecular mechanisms of the effect of erianin on DLBCL cells. Erianin was labeled with biotin or rhodamine, and its target proteins were identified using pull-down assays combined with proteomics, cellular thermal shift assays, and molecular docking. CompuSyn software was used to analyze the combination index of erianin and doxorubicin (DOX) for evaluating their synergistic anti-DLBCL effects. Results from the in vitro experiments were subsequently validated using in vivo experiments.</p><p><strong>Results: </strong>Erianin inhibited the proliferation of DLBCL cells, promoted G2/M phase arrest, and induced cell death. Mechanistically, erianin induced inhibition of the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) signaling pathway in DLBCL cells, which led to increased reactive oxygen species (ROS) formation, inflammasome activation, and caspase-1/Gasdermin D (GSDMD)-dependent pyroptosis. Erianin was found to bind to the S100A9 protein, suggesting a potential mechanism through which erianin activates downstream signaling pathways. Moreover, erianin synergistically enhanced the effects of DOX on DLBCL.</p><p><strong>Conclusions: </strong>Our study demonstrates that erianin binds to S100A9 and suppresses the PI3K/AKT signaling pathway in DLBCL cells, thereby elevating ROS levels, activating the inflammasome, and triggering caspase-1/GSDMD-dependent pyroptosis. Moreover, erianin increased the sensitivity of DLBCL cells to DOX both in vitro and in vivo . The effects of erianin on DLBCL imply its potential in the development of promising new drugs against this disease.</p>","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":" ","pages":"2808-2820"},"PeriodicalIF":9.1,"publicationDate":"2026-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13593181/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144882222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CircRERE promotes myocardial ischemia/reperfusion injury by increasing UHRF1 mRNA decay through targeting PUM2 to reduce Drp1 promoter methylation.","authors":"Shihui Fu, Yan Nie, Ping Ping, Zhitao Gao, Yali Zhao, Wang Wang, Zhirui Li, Qiong Liu","doi":"10.1097/CM9.0000000000003757","DOIUrl":"10.1097/CM9.0000000000003757","url":null,"abstract":"<p><strong>Background: </strong>Myocardial ischemia/reperfusion (I/R) injury contributes significantly to cardiac dysfunction following myocardial infarction, mainly due to excessive oxidative stress and mitochondrial injury. Despite advances in reperfusion therapies, secondary injuries remain a challenge, necessitating deeper insight into the molecular mechanisms underlying I/R injury. In the present study, we aim to investigate the roles of circular ribonucleic acid (circRNA) RERE ( circRERE ) in myocardial I/R injury.</p><p><strong>Methods: </strong>Hypoxia/reperfusion (H/R) cells and an I/R mouse model were used. Cell apoptosis was assessed using flow cytometry and terminal deoxynucleotidyl transferase dUTP nick-end labeling staining. The cell reactive oxygen species (ROS) and secreted lactate dehydrogenase (LDH) levels were measured. Quantitative reverse transcription polymerase chain reaction, western blot, immunofluorescence staining, and immunohistochemistry were used to assess mRNA and protein expression. MitoTracker and electron microscopy were used to examine mitochondrial morphology. The interactions between circRERE , Pumilio 2 (PUM2), ubiquitin-like with plant homeodomain and ring finger domain 1 (UHRF1), and dynamin-related protein 1 (Drp1) were validated by RNA immunoprecipitation, RNA pull-down, and/or chromatin immunoprecipitation assays. I/R-induced pathological changes in cardiac tissues were evaluated by hematoxylin and eosin (H&E) and 2,3,5-triphenyltetrazolium chloride (TTC) staining. Statistical analyses were performed using one-way analysis of variance and Student's t -test, with P <0.05 considered a statistically significant difference.</p><p><strong>Results: </strong>CircRERE expression was significantly elevated during I/R injury (about a 3.1-fold increase, P <0.001). CircRERE knockdown reduced ROS levels by 39.5% ( P <0.01), improved mitochondrial membrane potential ( P <0.01), and decreased apoptotic rates ( P <0.001). Mechanistically, circRERE promoted UHRF1 mRNA decay by interacting with PUM2, leading to reduced Drp1 promoter methylation, increased Drp1 expression, and subsequent mitochondrial fission and dysfunction. In vivo , circRERE knockdown significantly reduced infarct size by 24.27% ( P <0.001), improved cardiac tissue morphology, and restored mitochondrial homeostasis.</p><p><strong>Conclusions: </strong>CircRERE exacerbated myocardial I/R injury by promoting UHRF1 mRNA degradation and mitochondrial dysfunction. Targeting the circRERE / UHRF1 /Drp1 axis may represent a novel therapeutic strategy against myocardial I/R injury.</p>","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":" ","pages":"2791-2807"},"PeriodicalIF":9.1,"publicationDate":"2026-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13592967/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144945037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Glioma microenvironment: Cellular crosstalk, immunosuppression, and novel therapeutic perspectives.","authors":"Yanjia Hu, Jian Liang, Jianguo Xu, Linjie Zhao","doi":"10.1097/CM9.0000000000004151","DOIUrl":"10.1097/CM9.0000000000004151","url":null,"abstract":"<p><strong>Abstract: </strong>Glioma, the most aggressive primary brain malignancy, arises from glial cells within the central nervous system. Despite aggressive treatment, the prognosis remains poor, with all patients expected to experience recurrence. An important component of glioma growth is the interaction with the other cells in the brain environs. This complex ecosystem, termed the tumor microenvironment (TME), includes recruited immune cells and the resident cells in the central nervous system. Glioma cells recruit myeloid cells and reprogram their phenotype to fuel tumor growth. Tumor cells and reprogrammed myeloid cells further suppress adaptive immune responses. Additionally, glioma co-opts normal brain cells-including endothelial cells, neurons, and astrocytes-to create a microenvironment favoring tumor progression. Following this phenotypic shift, normal cells synergize with tumor cells to drive proliferation, invasion, immunosuppression, and angiogenesis. This review integrates recent advances in understanding the multidimensional interactions within the glioma TME, including insights gained from single-cell and spatial transcriptomics approaches that reveal its heterogeneous architecture and functional niches. By elucidating the underlying cellular and molecular mechanisms, we highlight how targeting the TME offers potential therapeutic opportunities to overcome treatment resistance and improve patient outcomes.</p>","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":" ","pages":"2690-2705"},"PeriodicalIF":9.1,"publicationDate":"2026-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13593177/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148257644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting disease relapse in plaque psoriasis patients treated with secukinumab: A multicenter retrospective cohort study.","authors":"Wen Chen, Zhihui Yang, Xiaowen Wang, Mingyue Wang, Yang Wang, Hang Li, Xiang Li, Ruoyu Li","doi":"10.1097/CM9.0000000000004148","DOIUrl":"10.1097/CM9.0000000000004148","url":null,"abstract":"","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":" ","pages":"2833-2835"},"PeriodicalIF":9.1,"publicationDate":"2026-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13592990/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148454906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Non-invasive methods for β-cell function assessment using a urine C-peptide model corrected for urine volume.","authors":"Jiachen Wang, Hao Dai, Yu Fu, Heng Chen, Hemin Jiang, Zhenzhen Fu, Tao Yang, Qi Fu","doi":"10.1097/CM9.0000000000004207","DOIUrl":"10.1097/CM9.0000000000004207","url":null,"abstract":"","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":" ","pages":"2830-2832"},"PeriodicalIF":9.1,"publicationDate":"2026-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13593170/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148757587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends and burden of maternal disorders in China from 1990 to 2023: Analysis of the Global Burden of Disease Study 2023.","authors":"Juan Juan, Yunfei Liu, Chao Yang, Guohua He, Xinyu Shu, Huixia Yang","doi":"10.1097/CM9.0000000000004213","DOIUrl":"10.1097/CM9.0000000000004213","url":null,"abstract":"<p><strong>Background: </strong>Maternal morbidity and mortality are one of the key indicators of social development and are among the most challenging public health problems. This study aimed to analyze the trends and burden of maternal disorders in China from 1990 to 2023.</p><p><strong>Methods: </strong>The crude and age-standardized prevalence, mortality, and disability-adjusted life years (DALYs) for maternal disorders from 1990 to 2023 were analyzed using data on maternal disorders in China from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2023. The changing trends of prevalence, mortality, and DALYs were evaluated by the average annual percentage change (AAPC) calculated using a log-transformed linear regression model. The ranks of the leading causes for maternal disorders in terms of prevalence, mortality, and DALYs in 1990, 2015, and 2023 were estimated to determine the impact of changes in the fertility strategy on maternal disorder patterns as China implemented the two-child policy in 2015.</p><p><strong>Results: </strong>In 2023, the age-standardized prevalence, mortality, and DALYs of maternal disorders among reproductive women aged 15-49 years in China were 193.04 (95% confidence interval [CI]: 192.56-193.54), 0.30 (95% CI: 0.28-0.32), and 27.78 (95% CI: 27.59-27.97) per 100,000 population, respectively. The prevalence showed a declining trend with fluctuations, and the mortality and DALYs both showed consistent decrease from 1990 to 2023, with AAPCs of -1.41% (95% CI: -1.92% to -0.90%), -10.64% (95% CI: -11.18% to -10.11%), and -9.37% (95% CI: -9.87% to -8.88%), respectively. In terms of the leading cause of death among the 10 available maternal disorders in GBD, maternal hemorrhage ranked first in 1990 (3.53 per 100,000) but decreased to third in 2015 (0.10 per 100,000) and 2023 (0.05 per 100,000). Among the 10 available maternal disorders in GBD 2023, the prevalence of maternal hypertensive disorders changed from first in 1990 to second both in 2015 and 2023. The other direct maternal disorders became the leading causes of prevalence and DALY during 2015 to 2023. Indirect maternal deaths ranked as the leading cause of mortality during 2015 to 2023.</p><p><strong>Conclusions: </strong>There has been a substantial decline in prevalence, mortality, and burden of maternal disorders in China during the past three decades. However, additional efforts are needed for decreasing the burden of maternal disorders, especially for maternal hypertensive disorders.</p>","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":" ","pages":"2741-2749"},"PeriodicalIF":9.1,"publicationDate":"2026-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13593077/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148705459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Poriae cutis triterpenes ameliorate metabolic-associated steatotic liver disease by inhibiting PXR/NLRP3 pathways.","authors":"Tingting Lyu, Wenjing Ma, Chen Zhang, Luzhe Yu, Rulin Wang, Daiyin Peng, Nianjun Yu, Lei Wang, Liang Yao, Weidong Chen, Yue Zhang, Yanyan Wang","doi":"10.1097/CM9.0000000000004147","DOIUrl":"10.1097/CM9.0000000000004147","url":null,"abstract":"","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":" ","pages":"2842-2844"},"PeriodicalIF":9.1,"publicationDate":"2026-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13593070/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148263023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}